Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under ...

GLP-1 drugs like Ozempic are transforming weight loss, but a new UVA study warns they're not improving a critical measure of ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

President Donald Trump's new European tariffs may spell bad news for Novo Nordisk, maker of Ozempic and Wegovy. As Axios ...

Some obese Americans on Medicare and Medicaid could get access to expensive weight loss drugs under a five-year experiment ...

A move to offer costly weight-loss drugs for obese Americans on Medicare and Medicaid may be in the works, but such a program ...

Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

But the study warns the drugs may also cause muscle loss, which is essential for strength, posture, and long-term health. Too much lean mass loss, researchers say, could increase the risk of heart ...